SilverBox Corp IV (SBXD)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Selling, General & Admin	0.72
Operating Expenses	0.72
Operating Income	-0.72
Interest & Investment Income	5.48
Other Non Operating Income (Expenses)	0.46
Pretax Income	5.22
Net Income	5.22
Net Income to Common	5.22
Shares Outstanding (Basic)	16
Shares Outstanding (Diluted)	16
EBIT	-0.72

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q